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569 
EVALUATING SYSTEMATIC REVIEWS AND META-
ANALYSES 
 
Lisa A. Bero, Ph.D.* 
If one’s first impression of the world’s clinical literature 
is that of its fearsome immensity; one’s second is likely to 
be that of its appallingly poor average quality. The two are 
obviously interconnected; the drug literature is 
overburdened by a vast volume of superfluous and even 
dangerous rubbish. The standards of medical journals range 
from the sublime (of which there are very few) to the 
disgraceful. 
Graham Dukes, MD MA LLM, 19771 
INTRODUCTION 
Information overload in the medical field is not a new problem. 
In fact, it just gets worse as more information of questionable 
validity accumulates. As much of this information appears as 
“scientific evidence” in the courtroom, there is a pressing need for 
law professionals to understand state-of-the-art methods for 
                                                 
 * Professor in the Department of Clinical Pharmacy at the Institute for 
Health Policy Studies, University of California, San Francisco. Dr. Bero thanks 
Nick Royle, CEO, Cochrane Collaboration for assistance with preparing figure 
2. 
1 Dr. Graham Dukes is currently with the Unit for Drug Policy Studies, 
University of Oslo. Having held senior positions with national regulatory 
authorities, World Health Organization (WHO), and World Bank (WB), he has a 
distinguished professional record. Graham Dukes has peerless experience in the 
areas of drug policy, legislation, regulation, utilization studies, information 
services, adverse reaction monitoring, medical risk management and 
professional training. He has assisted numerous countries in the development of 
new polices, reorganization of regulatory systems, the design of new 
pharmaceutical legislation and supply structures. 
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critically appraising and summarizing massive amounts of 
scientific data. 
Systematic reviews and meta-analyses are powerful methods 
for gathering, critiquing and summarizing medical and scientific 
information. Systematic reviews are combinations of results that 
adhere to pre-defined methods, but that may not result in 
quantitative combination of the data. Meta-analysis is a 
quantitative approach to systematically combining the results of 
previous studies. A meta-analysis that does not start as a 
systematic review may be published, but, for reasons described 
below, it would not be a high quality review. 
The use of meta-analyses and systematic reviews to guide 
clinical practice is increasing.2 Systematic reviews and meta-
analyses of randomized controlled trials are the most 
methodologically rigorous forms of evidence to evaluate the 
effectiveness of therapeutic interventions, particularly 
pharmacotherapy.3 They often form the foundation for practice 
guidelines, clinical decision support systems, drug formulary 
decisions, and drug payment schemes. 
Healthcare practitioners, researchers, and anyone interested in 
answering scientific or medical questions would like to be able to 
turn to the ideal report of research findings. This ideal report 
would, in one place, summarize data from all studies available on a 
particular topic. The studies would be critically evaluated using 
unbiased methods. The report would be instantly accessible and 
kept up to date as new data accumulated. 
The Cochrane Collaboration, whose logo is illustrated in 
Figure 1,4 aspires to provide this ideal source of information. The 
Cochrane Collaboration was founded in 1993 and named after 
                                                 
2 Lisa A. Bero & Drummond Rennie, The Cochrane Collaboration: 
Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of 
Healthcare, 274 JAMA 1935, 1935-38 (1995); Lisa A. Bero & Alejandro R. 
Jadad, How Consumers and Policymakers can use Systematic Reviews for 
Decision Making, 127 ANN. INTERNAL MED. 37, 37-42 (1997); Deborah J. Cook 
et al., Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions, 
126 ANN. INTERNAL MED. 376, 376-80 (1997). 
3 Cook et al., supra note 2. 
4 See infra note 65. 
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British epidemiologist, Archie Cochrane. In 1979, Cochrane wrote 
that “[i]t is surely a great criticism of our profession that we have 
not organized a critical summary, by specialty or subspecialty, 
adapted periodically, of all relevant randomized controlled trials.”5 
The long term goal of the Cochrane Collaboration is to develop 
these critical summaries of all trials of all healthcare interventions. 
The Cochrane Collaboration is an international non-profit 
organization that aims to help people make well-informed 
decisions about healthcare by preparing, maintaining and 
promoting the accessibility of systematic reviews of the effects of 
healthcare interventions. It produces and disseminates systematic 
reviews of healthcare interventions and promotes the search for 
evidence in the form of clinical trials and other studies of 
interventions.6 The major product of the Collaboration is the 
Cochrane Database of Systematic Reviews, which is published 
quarterly as part of the Cochrane Library.7 
                                                 
5 Archie L. Cochrane, 1931-1971: A Critical Review, with Particular 
Reference to the Medical Profession, in LONDON: OFFICE OF HEALTH 
ECONOMICS, MEDICINES FOR THE YEAR 2000 1-11 (1979). 
6 The Cochrane Collaboration Home Page, http://www.cochrane.org (last 
visited May 9, 2006). 
7 See infra note 65. The Cochrane logo (Figure 1) is a meta-analysis of 7 
randomized controlled trials comparing a short, inexpensive course of a 
corticosteroid to placebo in women with premature labor. The data for these 
trials are shown as “odds ratios,” meaning the odds of patients in the treated 
group having the outcome divided by the odds of the patients in the placebo 
group having the outcome. An odds ratio is just one way of representing the 
point estimate, or result, of a trial. Each horizontal line represents the results of 
one trial; the middle of the line is the point estimate for the odds ratio and the 
ends of the line represent the variability around this estimate. The shorter the 
line, the larger the trial and the more certain the result. In the case of the 
Cochrane logo, an odds ratio of less than one will show a favorable effect of the 
treatment because this would mean that the odds of a woman in the 
corticosteroid group having a baby die from complications of premature labor 
would be less than the odds of a woman in the placebo group. As seen in the 
figure, the seven trials all yield slightly different point estimates or odds ratios. 
The diamond represents the statistical combination of the results of all seven 
trials. The vertical line indicates an odds ratio of one, or the position at which 
there would be no difference in outcome between the treated and control groups. 
If a horizontal line touches the vertical line, it means that that particular trial 
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The validity of a systematic review depends on the extent to 
which the methods of the review reduce random error and 
systematic bias. Systematic reviews reduce bias because they are 
conducted according to strictly defined methods. A good 
systematic review contains a focused question, an explicit and 
comprehensive search strategy, explicit inclusion and exclusion 
criteria that are uniformly applied, a rigorous critical appraisal of 
each identified study and, if appropriate, a quantitative summary of 
the evidence.8 
Part I of this paper discusses the importance of systematic 
reviews and meta-analyses for evidence-based medicine by 
highlighting the benefits systematic reviews provide researchers 
and funders over reliance on individual studies. Part II offers a 
primer on how to evaluate a systematic review to best eliminate 
bias in the review and provides some general guidelines for each 
step in the optimal review process. 
I. THE IMPORTANCE OF SYSTEMATIC REVIEWS 
Systematic reviews are a way of dealing with the massive 
information overload that is typical of clinical medicine. 
Systematic reviews are an efficient scientific technique for 
gathering, critiquing and summarizing large amounts of 
information. A systematic review allows the reader to see when 
scientific findings are consistent. When studies that are done in 
slightly different ways or in slightly different populations reach the 
same answer, we can assume that the results may be generalizable 
to a wider population. On the other hand, systematic reviews allow 
for the exploration of inconsistencies and conflicts in the results of 
individual studies. By presenting the same information on all 
studies in the systematic reviews, the review allows the reader to 
determine whether divergent results might be due to differences in 
                                                 
found no clear difference between the treatments. The position of the diamond 
to the left of the vertical line indicates that the treatment studied is beneficial. 
The logo demonstrates that corticosteroid therapy for women in premature labor 
is an effective intervention. 
8 Cynthia D. Mulrow, The Medical Review Article: State of the Science, 
106 ANN. INTERNAL MED. 485 (1987). 
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the methods of the original studies, differences in the experimental 
intervention tested, or variability in the characteristics of the 
populations tested. 
Increasing the power, or sample size, of a study reduces 
random error. The larger the study, the more likely that the results 
will be distributed around the true effect. In smaller studies, due to 
chance and random error, the results are less likely to represent the 
true effect. Meta-analysis increases the power of a study because it 
combines the results of a number of small studies into one study 
with a larger sample size. Thus, meta-analysis increases the 
precision of an estimate of an effect by decreasing the variability 
around the estimate as the sample size increases. 
A common myth about meta-analysis is that if enough studies 
are combined, the results will always be statistically significant, or 
demonstrate an effect. This is not the case, however, as illustrated 
by a meta-analysis of randomized, controlled trials of prophylactic 
lidocaine for acute myocardial infarction.9 In this meta-analysis, 
the results of eight small randomized controlled trials of lidocaine 
were combined. When the studies were statistically combined into 
a meta-analysis of almost 9,000 patients, the summary estimate 
remained statistically non-significant, thus showing there was no 
effect of lidocaine. 
Another valuable contribution of systematic reviews is that 
they can help set research agendas (and avoid embarrassment of 
researchers) by identifying what questions have been answered, as 
well as gaps in understanding. This contribution is best illustrated 
with the technique of cumulative meta-analysis, which means that 
each study in the meta-analysis is added in consecutively.10 Figure 
2,11 represents the results of a cumulative meta-analysis of 
randomized controlled trials examining the effect on mortality of 
                                                 
9 Elliott M. Antman et al., A Comparison of Results of Meta-analyses of 
Randomized Control Trials and Recommendations of Clinical Experts: 
Treatments for Myocardial Infarction, 268 JAMA 240, 242-44 (1992). 
10 Joeseph Lau et al., Cumulative Meta-analysis of Clinical Trials Builds 
Evidence for Exemplary Medical Care, 48 J. CLIN. EPIDEMIOL. 45, 45-47, 59-60 
(1995). 
11 See infra note 66.  
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thrombolytic therapy following an acute myocardial infarction.12 
As shown in the figure, after the enrollment of approximately 
6,000 patients in 27 trials over a 20 year period, it was clear that 
treatment with thrombolytic therapy reduced mortality. As more 
patients were enrolled in more trials, the odds ratio did not change 
much, although the variability around the odds ratio decreased as 
the sample size of the cumulative meta-analysis increased. Thus, 
approximately 42,000 people participated in 43 more trials that 
were not needed to determine if a thrombolytic therapy effectively 
reduces mortality after a myocardial infarction. Meta-analysis is a 
valuable tool for helping researchers and funders decide when 
more research is needed to answer a clinical question. 
If a good systematic review is available, should one rely on the 
results of an individual study to answer a clinical question? The 
answer is no. Systematic reviews and meta-analyses have become 
the gold standard for evidence-based medicine. Evidence-based 
medicine emphasizes the examination of evidence from clinical 
research over intuition, unsystematic clinical observations, and 
pathophysiological rationale for clinical decision making.13 
Because systematic reviews and meta-analyses of randomized 
controlled trials are designed to reduce bias and generalize results 
across patients, they are considered to be the top of the “hierarchy 
of evidence” for evidence-based medicine.14 Conclusions drawn 
from a single randomized controlled trial are generally considered 
weaker because they are based on smaller sample size and do not 
generalize across different patients.15 The remainder of this paper 
will present some general guidelines for evaluating the validity of 
                                                 
12 Antman, supra note 9, at 240-48. Joseph Lau et al., Cumulative Meta-
analysis of Therapeutic Trials for Myocardial Infarction, 327 NEW ENG. J. MED. 
248, 251 (1992). 
13 David L. Sackett & W.M. Rosenberg, The Need for Evidence-based 
Medicine, 88 J. ROYAL SOC’Y MED. 620, 620-24 (1995); David L. Sackett, 
Evidence-based Medicine, 21 SEMINARS IN PERINATOLOGY 3, 3-5 (1997). 
14 Gordon H. Guyatt et al., Users’ Guides to the Medical Literature: IX. A 
Method for Grading Healthcare Recommendations, 274 JAMA 1800 (1995); 
Cook et al., supra note 2. 
15 Joseph C. Cappelleri et al., Large Trials vs. Meta-analysis of Smaller 
Trials: How Do Their Results Compare?, 276 JAMA 1332, 1332-38 (1996). 
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systematic reviews. 
II. EVALUATING SYSTEMATIC REVIEWS 
There are many possible sources of bias in reviews, including 
the framing of the research question, the selection of studies to be 
included, the extraction of data from and critical appraisal of the 
included studies, and the analysis. It is sometimes difficult to 
detect the source of bias. For example, reviews of studies of 
adverse effects related to exposure to secondhand smoke are more 
likely to conclude that secondhand smoke is not harmful when the 
authors of the reviews are affiliated with the tobacco industry, 
regardless of the methodological quality of the review, whether it 
was published in a peer-reviewed journal, or other factors.16 
One way to avoid bias in a review is to develop a protocol for 
the review before commencement and adhere to the protocol 
regardless of the results of the review.17 A reader of the review can 
then determine whether the authors conducted it according to the 
systematic methods proposed. When the reviews are completed, 
the readers can be assured that the authors adhered to the methods 
of the protocol and did not change the methods after they started 
the review. Adherence to a strict protocol can sometimes result in 
reviews where no studies that meet the criteria for the review can 
be found. However, as mentioned above, these reviews are still 
useful for identifying gaps in the research literature. 
A good protocol (and completed review) should contain the 
following sections: 1) an objective or research question, 2) criteria 
for selecting studies for the review, 3) a search strategy for studies, 
4) methods for assessing the validity of included studies, 5) 
methods for selecting studies for the review, 6) methods for 
collecting data from the studies, and 7) an analysis plan. 
                                                 
16 Deborah E. Barnes & Lisa A. Bero, Why Review Articles on the Health 
Effects of Passive Smoking Reach Different Conclusions, 279 JAMA 1566, 
1566-70 (1998). 
17 The Cochrane Library publishes protocols of reviews. 
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1. Objectives 
Every systematic review should contain a precise statement of 
the primary objective or research question. The objective should 
include a description of the population to be tested, the 
intervention or exposure to be tested, the treatment for the 
comparison group, and the outcome.18 In other words, “What is 
being tested to change what outcome in whom?”19 
Any prior hypotheses and comparison groups should be stated. 
This includes pre-specified subgroup analysis. For example, one 
might hypothesize that a drug will reduce hypertension only in 
non-obese patients. Thus, the review should contain an objective 
stating that data from obese patients will be analyzed separately 
from data from non-obese patients. Specifying subgroup analysis 
after data collection for the review has already begun can be a 
“fishing expedition” or “data dredging” for statistically significant 
results and is not appropriate. 
2. Criteria for Selection of Studies for the Review 
The biased citation of studies in a review can be a major source 
of error in the results of the review.20 Authors of reviews can 
influence their conclusions by citing only studies that support their 
preconceived, desired outcome. The clearly stated objective of the 
review determines the criteria used to select studies for inclusion in 
                                                 
18 Andrew D. Oxman et al., Users’ Guides to the Medical Literature: VI. 
How to Use an Overview, 272 JAMA 1367, 1367-71 (1994). 
19 Some examples of clear objectives are: 
• Do corticosteroids, compared to no treatment, prevent pre-term labor in 
pregnant women? 
• Does prophylactic lidocaine, compared to placebo, prevent acute 
myocardial infarction in patients who have already had a myocardial 
infarction? 
• Do calcium channel blockers lower blood pressure in patients with 
hypertension compared to placebo? A related question with a different 
outcome of interest would be, “Do calcium channel blockers reduce 
mortality in patients with hypertension compared to placebo?” 
20 Paul F. Neihouse & Susan C. Priske, Quotation Accuracy in Review 
Articles, 23 DICP 594, 594-96 (1989). 
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the review. The eligibility criteria should include a description of 
1) the participants in the studies (e.g., children, men or women 
with recent heart attacks), 2) the interventions or exposures (e.g., a 
drug, chemical exposure), 3) the outcome measures (e.g., 
mortality, heart attack), and 4) the study design (e.g., randomized 
controlled trial, observational study). As mentioned above, 
systematic reviews of randomized controlled trials are considered 
one of the most rigorous types of clinical evidence. In a 
randomized controlled trial, the only difference between the two 
groups being compared is the experimental intervention. Thus, 
systematic reviews, particularly those examining the effects of 
therapeutic interventions, may include only randomized controlled 
trials. 
The types of study designs to be included in a review will vary 
with the research objective. For example, the effects of 
environmental toxins are not typically examined using randomized 
controlled trials. Thus, a systematic review of the effects of a 
potential environmental hazard will include studies of 
observational designs, such as cohort or case control studies.21 
Even qualitative studies, such as focus groups or interview studies, 
can be combined using systematic review methods. For example, a 
review of qualitative studies on barriers to childhood vaccination 
identified several consistent areas that are obstacles to children 
receiving immunizations.22 
3. Search Strategy for Identification of Studies 
After the inclusion criteria for studies are clearly specified, a 
comprehensive search strategy must be developed.23 The search 
should be as comprehensive as possible. The review should specify 
                                                 
21 See Barnes & Bero, supra note 16. 
22 Edward Mills et al., Systematic Review of Qualitative Studies Exploring 
Parental Beliefs and Attitudes Towards Childhood Vaccination Identifies 
Common Barriers to Vaccination, 58 J. CLIN. EPIDEMIOL. 1081, 1081-88 (2005). 
23 Carl Counsell & Hazel Fraser, Identifying Relevant Studies for 
Systematic Reviews, 310 BMJ 126 (1995); Maureen O. Meade & W. Scott 
Richardson, Selecting and Appraising Studies for a Systematic Review, 127 
ANN. INTERNAL MED. 531, 531-37 (1997). 
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the exact dates of the search and whether there were any language 
restrictions. 
Unfortunately, a print review article is out of date as soon as it 
is published. Thus, regular updating of reviews, such as those in 
the Cochrane Library, is essential for ensuring the accuracy of the 
information. Although the end date of a search for studies should 
be as recent as possible (and regularly updated), the start date of 
the search should be appropriate to the question. For example, if no 
trials of a particular drug were conducted before 1985, it is not 
necessary to extend the search prior to that date. In some cases, the 
circumstances under which research is conducted may change. For 
example, the definition of the AIDS diagnosis was refined during 
the late 1980’s. Trials of HIV/AIDS therapies conducted in the 
early 1980’s may have included different populations than those 
conducted in the 1990’s. Thus, reviews of these therapies should 
clearly specify the rationale for the search dates. 
Many systematic reviewers restrict their searches to English 
language-only studies. However, this is primarily for the sake of 
convenience and can introduce a number of limitations. The 
methodological quality of clinical trials does not vary by language 
of the publication, so quality concerns are not a good justification 
for language restrictions.24 Furthermore, the results of systematic 
reviews can change completely when the review includes only 
English language studies or studies in any language. Gregoire 
found that in at least one out of 36 consecutive meta-analyses the 
exclusion of papers for language reasons produced results different 
from those which would have been obtained if this exclusion 
criteria had not been used.25 As long as a study meets the inclusion 
criteria for the review, it should be included regardless of the 
language of its publication. 
                                                 
24 D. Moher et al., Completeness of Reporting of Trials Published in 
Languages Other Than English: Implications for Conduct and Reporting of 
Systematic Reviews, 347 LANCET 363, 363-36 (1996); Matthias Egger et al., 
Language Bias in Randomised Controlled Trials Published in English and 
German, 350 LANCET 326, 326-29 (1997). 
25 G. Gregoire et al., Selecting the Language of the Publications Included in 
a Meta-Analysis: Is There a Tower of Babel Bias?, 48 J. CLIN EPIDEMIOL. 159, 
159-63 (1995). 
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Electronic databases of research articles are a good starting 
place to search for studies that meet the inclusion criteria for a 
systematic review. MEDLINE or PubMed (produced for free by 
the National Library of Medicine) is the most commonly used 
database. However, a PubMed search identifies only about 50% of 
randomized controlled trials published in journals that are indexed 
by MEDLINE. Comparison of a MEDLINE search with a “gold 
standard” search based on manual, page-by-page searching of 
journals for randomized controlled trials found that MEDLINE 
was not good at detecting trials.26 The poor performance of 
MEDLINE is due to the improper indexing of randomized 
controlled trials, as well as the inappropriate use of search terms.27 
Clearly, searching MEDLINE alone is inadequate for identifying 
randomized controlled trials. Supplementing the MEDLINE search 
with other electronic database searches can be useful. EMBASE 
indexes more than 100 journals that are not indexed in MEDLINE, 
including many non-English language journals, and LILACS is the 
largest electronic database of Spanish-language medical journals. 
Specialty electronic databases can also be useful, depending on the 
topic of the research questions. CINAHL, PsychLit, CancerLit and 
BIOSIS are examples of specialty databases. 
As all electronic databases have limitations, a good review 
should employ additional methods for identifying studies that meet 
the inclusion criteria. Checking the reference lists of studies that 
are identified in the electronic searches often identifies additional 
studies. In addition, citation databases, such as Web of Science, 
can locate additional studies. These databases identify articles that 
cite the studies that were identified in the initial electronic search. 
Lastly, hand searching or the manual, page-by-page searching of 
journals for randomized, controlled trials is the gold standard for 
identifying studies. The Cochrane Collaboration has led an effort 
in hand searching journals to identify trials and these trials are 
indexed in the Cochrane Library.28 
                                                 
26 Kay Dickersin et al., Identifying Relevant Studies for Systematic Reviews, 
309 BMJ 1286, 1286-91 (1994). 
27 Id. 
28 Id. 
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Systematic reviewing and meta-analysis proceeds under the 
assumption that a complete and representative sample of relevant 
studies is available for analysis.29 However, because access to 
relevant studies is frequently limited to published studies, 
systematic reviews and meta-analyses are particularly vulnerable 
to biases that may affect the publication of studies. The majority of 
methodologists and journal editors now believe that unpublished 
data should be included in systematic reviews, suggesting 
widespread belief that important data remain unpublished.30 
The problem of publication bias, the tendency for studies 
showing statistically significant results to be published and 
published more quickly than studies with statistically non-
significant results, poses a serious challenge to identifying studies 
for systematic reviews. First identified in 1959,31 publication bias 
raises the concern that statistically significant study results may 
dominate the research record, thus reducing the range of evidence 
on which systematic reviews and meta-analyses are based.32 A 
recent study modeling the probability of finding statistically 
significant findings that are not correct has concluded that “most 
published research findings are false.”33 Most studies also show 
                                                 
29 Jerome M. Stern & R. John Simes, Publication Bias: Evidence of 
Delayed Publication in a Cohort Study of Clinical Research Projects, 315 BMJ 
640, 640-45 (1997). 
30 Debra J. Cook et al., Should Unpublished Data Be Included in Meta-
analyses? Current Convictions and Controversies, 269 JAMA 2749, 2749-53 
(1993). 
31 Theodore D. Sterling, Publication Decisions and Their Possible Effects 
on Inferences Drawn from Tests of Significance - or Vice Versa, 54 J AM. STAT. 
ASS’N 30, 30-34 (1959). 
32 Kay Dickersin et al., Publication Bias and Clinical Trials, 8 CONTROL 
CLININCAL TRIALS 343, 343-53 (1987); Phillipa J. Easterbrook et al., 
Publication Bias in Clinical Research, 337 LANCET 867, 867-72 (1991); 
Anastasia L. Misakian & Lisa A. Bero, Publication Bias and Research on 
Passive Smoking: Comparison of Published and Unpublished Studies, 280 JAMA 
250, 250-53 (1998). 
33 John P.A. Ioannidis, Why Most Published Research Findings are False, 
2 PLOS MEDICINE 101, 101-06 (2005), available at 
http://medicine.plosjournals.org/archive/1549-1676/2/8/pdf/10.1371_journal. 
pmed.0020124-S.pdf. 
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that not only statistical significance but a large sample size is also 
associated with publication, so that small, statistically non-
significant studies are rarely published. Thus, the results of 
systematic reviews and meta-analyses can be skewed in favor of 
new treatments showing positive initial results.34 Publication bias 
poses a particular threat to the reliability and validity of systematic 
reviews and meta-analysis by leading to spuriously large treatment 
effects in early meta-analyses of the available evidence.35 
Thus, authors of systematic reviews must attempt to identify 
unpublished and ongoing studies through a variety of methods. 
Searching the abstracts of conference proceedings, of which only 
about 50% are published as full journal articles,36 is one 
mechanism for identifying unpublished studies. Personal 
communication with investigators who are active in the field is 
another method. Searching clinical trial registries is one of the 
most promising methods for identifying unpublished data. 
Registration of clinical trials is one method that has been 
proposed to reduce publication bias.37 The exposure of notable 
cases of data suppression from clinical trials prompted the 
International Committee of Medical Journal Editors and its 11 
member journals to require, as a condition of consideration for 
publication, registration of clinical trials in a public trials 
registry.38 Although extensive debate about the specific content of 
trial registries continues, the increasing availability of such 
registers will make it easier to identify unpublished studies for 
systematic reviews. 
                                                 
34 John P.A. Ioannidis et al., Issues in Comparisons Between Meta-analyses 
and Large Trials, 279 JAMA 1089, 1089-93 (1998). 
35 Id. 
36 Roberta W. Scherer et al., Full Publication of Results Initially Presented 
in Abstracts: A Meta-Analysis, 272 JAMA 158, 158-62 (1994). 
37 Robert John Simes, Publication Bias: The Case for an International 
Registry of Clinical Trials, 4 J. CLINICAL ONCOLOGY 1529, 1529-41 (1986). 
38 Kay Dickersin & Yuan I. Min, Publication Bias: The Problem that 
Won’t Go Away, 703 ANN. N.Y. ACAD. SCI. 135, 146-48 (1993); Catherine D. 
DeAngelis et al., Clinical Trial Registration: A Statement from the International 
Committee of Medical Journal Editors, 292 JAMA 1363, 1363-64 (2004). 
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4. Assessment of Methods Used to Reduce Bias in the Selected 
Studies 
Bias is the combination of various design, data, analysis and 
presentation factors that tend to produce statistically significant 
research results that are not true.39 Various factors can lead to 
statistically significant outcomes in randomized controlled trials of 
drug efficacy, including framing of the research question, design 
and analysis of the study, and conduct of the study.40 Reporting (or 
not) of the full results or selective reporting of outcomes can also 
contribute to the problem of publication bias.41 One criticism of 
meta-analyses and systematic reviews is: “Garbage in, garbage 
out.” This means that if poorly designed and executed studies that 
fail to minimize bias are included in a systematic review, the 
results of the review will not be valid. Therefore, it is essential that 
the studies that are included in a systematic review are evaluated 
for their methodological quality—the methods used to reduce bias. 
The tools used to evaluate methodological quality should be 
specific to the study design being evaluated. As most evaluation 
tools have been developed to assess the quality of randomized 
controlled trials, the following section will focus on the evaluation 
of trials. However, instruments for assessing the methods of 
observational and qualitative studies are also available.42 
5. How Do We Measure Quality? 
Dozens of instruments for assessing the methodological quality 
                                                 
39 Ioannidis, supra note 33. 
40 Cochrane Collaboration, supra note 6. 
41 Id.; Richard Smith, Medical Journals are an Extension of the Marketing 
Arm of Pharmaceutical Companies, 2 PLoS Med. 364, 364-66 (2005), available 
at http://medicine.plosjournals.org/archive/1549-1676/2/5/pdf/10.1371_ 
journal.pmed.0020138-L.pdf. 
42 Andrew D. Oxman & David L. Sackett, Users’ Guides to the Medical 
Literature: I. How to Get Started. The Evidence-Based Medicine Working 
Group, 270 J. AM. MED. ASS’N 2093, 2093-95 (1993); Mildred K. Cho & Lisa 
A. Bero, Instruments for Assessing the Quality of Drug Studies Published in the 
Medical Literature, 272 J. AM. MED. ASS’N 101, 101-04 (1994). 
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of randomized controlled trials exist,43 including some frequently 
used instruments that contain from 3 to 22 items.44 In 1995, Moher 
examined 25 published scales and 9 checklists for measuring the 
methodological quality of randomized controlled trials.45 Most of 
these instruments calculate a quality “score” for the randomized 
controlled trial. 
There are several problems with all of these quality assessment 
instruments. First, reliability and validity have not been measured 
for most of them. A reliability measurement would provide 
information on how often multiple coders, using the instruments 
independently, would derive the same score. A validity measure 
would provide information on whether the items assessed in the 
instrument are truly evaluating methods that reduce bias. 
Second, most methodological quality assessment instruments 
combine the evaluation of reporting and actual study design. If two 
studies that are designed in an identical way are published in 
different journals, one may be reported more completely than the 
other. The more completely reported study would have a better 
quality score, although it is not truly a better designed study. In 
order to reduce the problem of variability in reporting, systematic 
reviewers often correspond with the authors of the studies to obtain 
information that is not in the study report. In addition, in recent 
years, many journals have developed reporting standards and have 
strengthened their policies regarding reporting of randomized 
controlled trials.46 
A third problem with the quality assessment instruments is that 
there is little empirical evidence to support differential weighting 
of the individual components of the quality scores. Individual 
characteristics of randomized controlled trials that are associated 
                                                 
43 See D. Moher et al., Assessing the Quality of Randomized Controlled 
Trials: An Annotated Bibliography of Scales and Checklists, 16 CONTROLLED 
CLINICAL TRIALS 62, 62-73 (1995); See also Moher, supra note 24. 
44 Thomas C. Chalmers et al., A Method for Assessing the Quality of a 
Randomized Control Trial, 2 CONTROLLED CLIN. TRIALS 31, 31-49 (1981); Cho 
& Bero, supra note 42. 
45 Moher, supra note 43. 
46 Colin Begg et al., Improving the Quality of Reporting of Randomized 
Controlled Trials: The CONSORT Statement, 276 JAMA 637, 637-39 (1996). 
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with bias have been identified in studies evaluating a variety of 
randomized controlled trials. These characteristics include 
inadequate randomization47 and concealment of allocation.48 
Concealment of allocation means that investigators, at the 
beginning of the study and before any patients are assigned to 
treatment, are unaware of the group to which a patient will be 
randomly assigned. Other characteristics of randomized controlled 
trials that are associated with bias are inadequate double blinding,49 
insufficient sample size,50 inappropriate choice of drugs to be 
compared,51 and inappropriate choice of statistical analysis.52 For 
                                                 
47 Thomas C. Chalmers et al., Controlled Studies in Clinical Cancer 
Research, 287 NEW ENG. J. MED. 75, 75-78 (1972); Graham A. Colditz et al., 
How Study Design Affects Outcomes in Comparisons of Therapy, 8 STAT. MED. 
441 (1989). 
48 Kenneth F. Schulz, Subverting Randomization in Controlled Trials, 274 
JAMA 1456, 1456-58 (1995) [hereinafter Schulz, Subverting Randomization]; 
Kenneth F. Schulz et al., Empirical evidence of bias. Dimensions of 
Methodological Quality Associated With Estimates of Treatment Effects in 
Controlled Trials, 273 JAMA 408, 408-12 (1995) [hereinafter Schulz, Empirical 
Evidence]. 
49 Colditz, supra note 47; Schulz, Empirical Evidence, supra note 48. 
50 John P. Ioannidis, Effect of the Statistical Significance of Results on the 
Time to Completion and Publication of Randomized Efficacy Trials, 279 JAMA 
281, 281-86 (1998); Misakian & Bero, supra note 32; Bodil Als-Nielsen et al., 
Association of Funding and Conclusions in Randomized Drug Trials: A 
Reflection of Treatment Effect or Adverse Events?, 290 JAMA 921, 921-28 
(2003); John P. Ioannidis et al., Randomised Trials Comparing Chemotherapy 
Regimens for Advanced Non-small Cell Lung Cancer: Biases and Evolution 
Over Time, 39 EUR. J. CANCER 2278, 2778-87 (2003); Bodil Als-Nielsen et al., 
Are Trial Size and Quality Associated with Treatment Effects in Randomised 
Trials?, 12TH ANNUAL COCHRANE COLLOQUIUM (2004). 
51 P.A. Rochon, et al., A Study of Manufacturer-Supported Trials of 
Nonsteroidal Anti-inflammatory Drugs in the Treatment of Arthritis, 154 
ARCHIVES INTERNAL MED. 157, 157-63 (1994); Helle Krogh Johansen & Peter 
C. Gotzsche, Problems in the Design and Reporting of Trials of Antifungal 
Agents Encountered During Meta-analysis, 282 JAMA 1752, 1752-59 (1999); 
Benjamin Djulbegovic et al., The Uncertainty Principle and Industry-Sponsored 
Research, 356 THE LANCET 635, 635-38 (2000); Daniel Safer, Design and 
Reporting Modifications in Industry-Sponsored Comparative 
Psychopharmacology Trials, 190 J. OF NERVOUS AND MENTAL DISEASE 583, 
583-92 (2002). 
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example, Schulz and colleagues found that estimates of treatment 
effects were exaggerated by 41% for inadequately concealed trials 
and by 17% for trials with inadequate double blinding.53 
Most quality assessment instruments assign points for using 
appropriate methods for each component of the randomized 
controlled trial, and sum these points into the quality score. Recent 
research suggests that these scores are not valid measures of 
methodological quality. Juni and colleagues determined that the 
use of different quality assessment scales using summary scores 
resulted in different conclusions of meta-analytic studies and 
proposed that specific components of methodological quality (e.g., 
concealment of allocation, blinding) should be individually 
assessed.54 Therefore, the use of quality scores to rate the studies 
included in a meta-analysis should be viewed with caution. 
Reporting each included study’s performance on the individual 
components of the quality score is more informative. 
Some systematic reviewers also report additional 
characteristics of included studies that are not strictly measures of 
methodological quality. For example, peer-reviewed journal 
articles are less likely to have statistically significant outcomes 
than non-peer-reviewed journal articles.55 In addition, a large body 
of evidence suggests that industry sponsorship of research is also 
associated with statistically significant results that are favorable to 
the sponsor. Two recent systematic reviews identified 19 studies 
examining the association of industry sponsorship and research 
outcomes.56 The magnitude of this observed association is variable. 
                                                 
52 Oscar H. Brook et al., Effects of Coaching by Community Pharmacists on 
Psychological Symptoms of Antidepressant Users: A Randomised Controlled 
Trial, 13 EUR. NEUROPSYCHOPHARMACOLOGY 347, 347-54 (2003); Jorge 
Gomez Cerezo et al., Outcome trials of COX-2 Selective Inhibitors: Global 
Safety Evaluation Does Not Promise Benefits, 59 EUR. J. CLINICAL 
PHARMACOLOGY 169, 169-75 (2003). 
53 Schulz, Subverting Randomization, supra note 48. 
54 Peter Juni et al., The Hazards of Scoring the Quality of Clinical Trials 
for Meta-analysis, 282 JAMA 1054, 1054-60 (1999). 
55 Mildred K. Cho & Lisa A. Bero, The Quality of Drug Studies Published 
in Symposium Proceedings, 124 ANN. INTERN. MED. 485, 485-89 (1996). 
56 Justin E. Bekelman et al., Scope and Impact of Financial Conflicts of 
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For example, review articles on the health effects of secondhand 
smoke exposure that are written by tobacco industry-supported 
authors are about 90 times more likely to conclude that secondhand 
smoke is not harmful than those that are written by authors not 
affiliated with the tobacco industry.57 Pharmaceutical industry-
sponsored drug studies are about 4 times more likely to have 
conclusions that favor the sponsor than those that are funded by 
non-pharmaceutical sponsors.58 Financial ties of investigators to 
their sponsors (e.g., stock ownership, consulting income, 
honoraria) are also associated with favorable research outcomes for 
the sponsor.59 
In summary, a systematic reviewer should use common sense 
measures to assess the methods of studies that are included in the 
review. The components that are assessed for each included study 
should focus on the key features of the study, should be 
empirically verified to influence outcome, and should be reported 
individually. Systematic reviewers must keep in mind that the 
evaluation of included studies could indicate that all the studies are 
flawed. In this case, no conclusions should be drawn from the 
studies included in the review. 
6. Methods for Selecting Studies for the Review, Extracting 
Data, and Appraisal of Studies 
Bias can be introduced during the selection of studies for 
inclusion in the review, as well as during the extraction and 
appraisal of data from the studies. Rigorous systematic reviewers 
often use two coders to independently select the studies from the 
list generated by the comprehensive search. The study selection 
should be done according to an explicit, written list of inclusion 
criteria. The coders should keep a written record of which criteria 
are met by each included study. The systematic review should also 
                                                 
Interest in Biomedical Research: A Systematic Review, 289 JAMA 454, 454-65 
(2003); Joel Lexchin et al., Pharmaceutical Industry Sponsorship and Research 
Outcome and Quality: Systematic Review, 326 BMJ 1167, 1167-70 (2003). 
57 Barnes & Bero, supra note 16, at 1566-70. 
58 Lexchin, supra note 6. 
59 Id. 
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include a table of excluded studies listing the reasons why each 
study was excluded. Such a table is useful for determining if bias 
was introduced into the study selection process. 
Two coders should also independently extract data from each 
included article and perform the quality assessment. Coders should 
be trained to use a data extraction form and be provided with a 
comprehensive set of instructions. Studies are sometimes assessed 
in random order using a computer random number generator in 
order to avoid the “training” effect that occurs as coders become 
more familiar with the data extraction instrument. 
Systematic reviews sometimes report the inter-rater agreement 
among multiple coders. A higher degree of agreement gives the 
reader more confidence that the selection and data extraction 
process did not introduce bias into the review. Often disagreements 
between coders can be resolved by consensus. In these cases, the 
consensus is often reported in the review. 
Reviewers are sometimes masked or blinded to the authors, 
authors’ institutions, or journals in which studies are published. 
However, complete blinding is difficult to achieve. Furthermore, 
there is no evidence that the masking of the data coders influences 
their selection or quality ratings.60 Therefore, it is less common for 
more recent systematic reviews to mask reviewers to the identity or 
sources of the studies. 
In summary, a systematic review should include a description 
of how the data collection was done and whether it is complete. 
The review should report that pre-tested, standardized data 
collection forms were used by multiple coders working 
independently. The methods to resolve disagreements among the 
coders should be described. In addition, efforts to obtain 
information that was missing from the original study reports 
should be described. For each study included in the review, data 
should be reported on: methods (including study design, individual 
                                                 
60 A.R. Jadad et al., Assessing the Quality of Reports of Randomized 
Clinical Trials: Is Blinding Necessary?, 17 CONTROLLED CLINICAL TRIALS 1, 1-
12 (1996); J.A. Berlin, Does Blinding of Readers Affect the results of Meta-
Analyses? University of Pennsylvania Meta-analysis Blinding Study Group, 350 
LANCET 185, 185-186 (1997); M. Clarke et al., Individual Patient Data Meta-
Analysis in Cancer, 77 BRITISH J. OF CANCER 2036, 2036-44 (1998). 
BERO MACRO CORRECTED 7-30-06.DOC 7/30/2006 12:34 PM 
588 JOURNAL OF LAW AND POLICY 
quality assessment components), participants, interventions, 
outcomes, and results (recorded in natural units and converted to a 
common effect size when possible). 
7. Data Synthesis—A Meta-analysis or Not? 
The last step in conducting a systematic review is to decide 
whether the data resulting from the search, data extraction and 
critical appraisal should be summarized quantitatively into a meta-
analysis. Data from the included studies should be quantitatively 
combined into a point estimate only if the participants, 
interventions, and outcomes are sufficiently similar. Although 
there are statistical techniques available to assess the heterogeneity 
of studies, deciding whether to combine results is largely a 
judgment call.61 Data from individual studies should never be 
statistically combined if no studies of good methodological quality 
exist or if a very broad question is being addressed. Thus, it is 
acceptable to combine oranges and oranges or apples and apples. 
Although it is not acceptable to statistically combine apples and 
oranges, it is acceptable to do a systematic review of apples and 
oranges as long as one is interested in fruit. For example, if a 
reviewer is interested in the efficacy of continuing medical 
education (CME) to change physician behavior, she will gather 
studies that have tested a variety of educational methods, such as 
lecture, problem-based small groups, or online courses. The 
reviewer could include all of these studies in a systematic review 
in order to get an overview of how CME is conducted. However, 
she should only statistically combine studies that tested the same 
intervention, i.e., lectures or small groups. 
“Vote counting” is not a valid method for summarizing the 
results of a systematic review. For example, if a review includes 11 
studies, one might conclude that the intervention is effective if 7 
studies found a statistically significant effect of the intervention 
and 4 did not. This vote count, however, negates many of the 
strengths of the systematic review technique, such as giving more 
                                                 
61 JOSEPH L. FLEISS ET AL., STATISTICAL METHODS FOR RATES AND 
PROPORTIONS 161-165 (John Wiley & Sons Inc. 3d ed. 2003). 
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weight to studies of better methodological rigor. If the most poorly 
designed studies are those that show the significant effect, the 
conclusion that the intervention works may be erroneous. Thus, 
statistical combination of data from similar studies allows for the 
weighting of the studies according to their design characteristics, 
sample size, or other features that might affect outcome. If a meta-
analysis is to be conducted, reviewers need to decide how the 
effect of the intervention examined in each study will be 
summarized. A discussion of the appropriateness of different 
summary statistics for a meta-analysis is beyond the scope of this 
paper.62 However, the statistical methods used to combine data for 
meta-analyses do not differ in principal from those used in primary 
research. Parametric, non-parametric, regression and Bayesian 
techniques can be used.63 The statistic chosen should be 
appropriate to the type of data analyzed and the reasons for 
choosing the statistic should be transparent. For example, 
dichotomous data, such as mortality, may be summarized as an 
odds ratio, relative risk, absolute risk difference, and number 
needed to treat.64 Continuous data, such as blood glucose or blood 
pressure, can be combined directly if measured on the same scale, 
or converted to a common metric if measured on different scales. 
Although different statistical methods are used to combine data 
from observational studies, the principles of combining similar 
studies and exploring reasons for heterogeneity among studies are 
the same.65 
                                                 
62 See Joseph Lau et al., Quantitative Synthesis in Systematic Reviews, 127 
SYSTEMATIC REV. SERIES 91, 91-101, (Cynthia Mulrow, MD, MSc & Deborah 
Cook MD, MSc eds., 1997). 
63 J. L. Fleiss, The Statistical Basis of Meta-Analysis, 2 STAT. METHODS 
MED. RES. 121, 121-45 (1993); I. Olkin, Statistical and Theoretical 
Considerations in Meta-Analysis, 48 J. CLIN. EPIDEMIOL. 133, 147 (1995); T.C. 
Smith et al., Bayesian Approaches To Random-Effects Meta-Analysis: A 
Comparative Study, 14 STAT. MED. 2685, 2685-99 (1995). 
64 J.C. Sinclair & M. B. Bracken, Clinically Useful Measures of Effect in 
Binary Analyses of Randomized Trials, 47 J. CLIN. EPIDEMIOL. 881, 881-89 
(1994). 
65 S. Greenland & M. P. Longnecker , Methods for Trend Estimation from 
Summarized Dose-response Data, with Applications to Meta-analysis, 135 AM J. 
EPIDEMIOL. 1301, 1301-09 (1992); W. Dumouchel, Meta-analysis for Dose-
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As described in the section on identifying studies, a good 
systematic reviewer will attempt to control for publication bias by 
conducting a comprehensive search for ongoing and unpublished 
studies. However, most meta-analyses also contain a statistical 
estimate of publication bias.66 These estimates tell the reader of the 
review whether publication bias exists among the studies included 
in the review and whether imputed results from unpublished 
studies might change the result of the review. 
H. Sensitivity Analyses 
Regardless of the statistical method used to combine data, 
sensitivity analyses should be conducted to measure the robustness 
of the summary effect. Variation in the characteristics of patients, 
interventions and study design features is inevitable across 
different types of studies. Therefore, it is important to explore 
whether any variation in the outcomes of the studies are due to 
these expected differences. A sensitivity analysis determines 
whether the summary point estimate is influenced by the 
assumptions made in conducting the systematic review. For 
example, a sensitivity analysis could be conducted in which the 
summary statistic is calculated first using all included studies, then 
recalculated after studies with certain characteristics are deleted 
from the analysis. If the results of the meta-analysis remain 
consistent, one has more confidence in the results of the review 
since it is not dependent on specific features of the included 
studies. Sensitivity analyses are often conducted by excluding 
studies that are of poor methodological quality, unpublished, or did 
not meet all of the inclusion criteria. Sensitivity analyses may also 
be conducted by reanalyzing data using a range of results from a 
                                                 
Response Models, 14 STAT. MED. 679, 679-85 (1995); S. J. Smith et al., On 
Combining Dose-response Data from Epidemiological Studies by Meta-analysis, 
14 STAT. MED. 531, 531-44 (1995). 
66 Colin B. Begg, Publication Bias, in THE HANDBOOK OF RESEARCH 
SYNTHESIS (Harris Cooper and Larry V. Hedges eds. 1994). Parametric tests are 
used when data are normally distributed, non-parametric tests are used when 
data are not normally distributed, regression techniques take multiple factors 
into account, and Bayesian techniques include assessments of prior probabilities. 
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trial (due to inconsistencies in reporting or how outcomes were 
measured), reanalyzing data using a range of results for missing 
data or reanalyzing the data using different statistics. 
CONCLUSION 
Systematic reviews and meta-analyses are powerful methods 
for gathering, critiquing and summarizing medical and scientific 
information. Meta-analysis is a quantitative approach to 
systematically combining the results of previous studies. 
Systematic reviews are combinations of results that adhere to 
pre-defined methods, but that may not result in quantitative 
combination of the data. The validity of a systematic review 
depends on the extent to which the methods of the review reduce 
random error and systematic bias. Systematic reviews reduce bias 
because they are conducted according to strictly defined methods 
that should be pre-specified in a protocol. A good systematic 
review contains a focused research question, an explicit and 
comprehensive search strategy, explicit inclusion and exclusion 
criteria that are uniformly applied by multiple coders, a rigorous 
critical appraisal of each identified study and, if appropriate, a 
quantitative summary of the evidence. 
 
 
Figure 167 
 
                                                 
67 The Cochrane Collaboration Home Page, see supra note 5.  
BERO MACRO CORRECTED 7-30-06.DOC 7/30/2006 12:34 PM 
592 JOURNAL OF LAW AND POLICY 
 
 
 
 
 
 
 
Figure 268 
                                                 
68 Antman, supra note 9, at 240-48.  
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